Evidence map›Paper›PMID 42699170›Full record

ArticleMaterials today. Bio2026

Endolysosomal routing combined with immune stimulation enhances anti-tumor efficacy of an HPV16 mRNA therapeutic vaccine.

Wenjie Song, Bo Ying, Peng Gao, Zhiyi Zhang, Xinpeng Ma, Jingshu Ma, Shuyuan Yang, Yan Wu, Dalin Wu, Jun Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenjie SongSchool of Biomedical Engineering, Sun Yat-sen University, Shenzhen, China.
Bo YingSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Peng GaoSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Zhiyi ZhangSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Xinpeng MaSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Jingshu MaSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Shuyuan YangSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Yan WuSuzhou Abogen Biosciences Co., Ltd., Suzhou, China.
Dalin WuSchool of Biomedical Engineering, Sun Yat-sen University, Shenzhen, China.
Jun WuBiological Science and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou, Guangdong, 511400, China.
Tao DuDepartment of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the widespread use of prophylactic vaccines, Human papillomavirus (HPV) related cancers persist as a substantial global health burden, highlighting the high demand for effective therapeutics. Signal peptide (SP) and major histocompatibility complex (MHC) class I trafficking domain (MITD) have been utilized in HPV messenger RNA (mRNA) therapeutic vaccines to improve MHC class I and II presentation. However, how antigen-processing modules (ubiquitin [Ub], SP-MITD, lysosome-associated membrane protein [LAMP]) and immune stimulators (granulocyte-macrophage colony-stimulating factor [GM-CSF], stimulator of interferon [IFN] genes [STING], CD4

Indexed as

ABO-208Human papillomavirusMajor histocompatibility complex class I trafficking domainMessenger RNA therapeutic vaccinePan-HLA-DR binding epitope

Identifiers

PMID42699170
PMCPMC13543989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.